Sunday, August 9, 2020

Hyd’s Biophore ramps up Favipiravir production.

Must Read

Will abide by what SC rules on Sushant probe, says Maha govt

Nagpur, Aug 8 : Though the Maharashtra government opposes a CBI probe in the Sushant Singh Rajput case, it...

Pics & videos of Saba Qamar dancing at historic mosque draws ire

Saba Qamar, Bilal Saeed in Wazir Khan mosque in Lahore/TwitterKARACHI: Social media users slammed Pakistani actress Saba...

LB Nagar MLA Sudhir Reddy, kin tested positive

Hyderabad: TRS MLA from LB Nagar segment Sudhir Reddy and his family members were tested positive for Corona, according...

Hyderabad: Hyderabad-based Biophore India Pharmaceuticals on Tuesday announced that it had completed the validation of Favipiravir and scaled-up its production.

Favipiravir is the active pharmaceutical ingredient (API) that can be used in the finished formulation of an antiviral drug approved by the Drug Controller General of India (DCGI) for mild to moderate cases of Covid-19.

Biophore has received the DCGI license to manufacture the API in India and has been cleared for export as well. It has also received approval in Turkey in collaboration with a local Turkish partner. The company said that it is in talks with several Indian partners to commercialize the product in India and with Bangladesh and Egypt-based companies for its export,

Biophore is also awaiting DCGI approval for a Favipiravir finished dosage form.

“The Covid-19 pandemic has emphasized the need for pharmaceutical companies to step up and develop effective solutions quickly, without compromising on safety. We have ensured that our favipiravir meets the highest standards of quality,” said Dr Manik Reddy Pullagurla, Founder and Chief Scientific Officer (CSO) of Biophore.

He said their manufacturing facilities comply with US and EU regulations and have stringent internal impurity controls and quality checks. “Meeting Favipiravir needs in India is our priority, and we have the capacity to scale up production of Favipiravir to meet local requirements, without compromising on our export commitments.”

Favipiravir is an antiviral agent that was initially discovered and developed because of its activity against another RNA virus, the influenza virus. Apart from India and Turkey, it has already been approved for use against Covid-19 in Russia and parts of the Middle Eastland advanced stage trials are currently underway in other parts of the world.

“Biophore’s Favipiravir is 100 per cent Made in India. This is what sets us apart from many other suppliers of this API. We are not dependent on any imports to produce Favipiravir. All starting materials and complex intermediates are either sourced locally or have been developed in-house for use. We are confident that this API will help our country move several steps forward in our united fight against Covid-19,” said Jagadeesh Babu Rangisetty, CEO, Biophore.

Subscribe us on The Siasat Daily - Google News

Latest News

Will abide by what SC rules on Sushant probe, says Maha govt

Nagpur, Aug 8 : Though the Maharashtra government opposes a CBI probe in the...

Pics & videos of Saba Qamar dancing at historic mosque draws ire

Saba Qamar, Bilal Saeed in Wazir Khan mosque in Lahore/TwitterKARACHI: Social media users slammed Pakistani actress Saba Qamar and singer Bilal Saeed...

LB Nagar MLA Sudhir Reddy, kin tested positive

Hyderabad: TRS MLA from LB Nagar segment Sudhir Reddy and his family members were tested positive for Corona, according to information.Sudhir Reddy wife, two...

State labour Minister Malla Reddy, wife test positive

Hyderabad: Despite all measures being taken by state government to prevent corona spread, leaders of the ruling party falling victims to positive cases. Labour...

Bernie Sanders mulls ‘Make Billionaires Pay Act’, zones in on Bezos, Musk, Zuckerberg

By Nikhila NatarajanNew York, Aug 8 : Three Senators, led by Bernie Sanders, have attracted global attention for introducing the “Make Billionaires Pay Act,”...

More Articles Like This